328 related articles for article (PubMed ID: 10996630)
1. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
Schadendorf D; Paschen A; Sun Y
Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630
[TBL] [Abstract][Full Text] [Related]
2. Cell-based vaccination against melanoma--background, preliminary results, and perspective.
Sun Y; Paschen A; Schadendorf D
J Mol Med (Berl); 1999 Aug; 77(8):593-608. PubMed ID: 10543391
[TBL] [Abstract][Full Text] [Related]
3. New approaches to the development of adenoviral dendritic cell vaccines in melanoma.
Butterfield LH; Vujanovic L
Curr Opin Investig Drugs; 2010 Dec; 11(12):1399-408. PubMed ID: 21154122
[TBL] [Abstract][Full Text] [Related]
4. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
Front Immunol; 2021; 12():623639. PubMed ID: 33692796
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral immunotherapy for melanoma.
Singh M; Overwijk WW
Cancer Immunol Immunother; 2015 Jul; 64(7):911-21. PubMed ID: 26050024
[TBL] [Abstract][Full Text] [Related]
7. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
[TBL] [Abstract][Full Text] [Related]
8. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
Sondak VK; Sosman JA
Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
[TBL] [Abstract][Full Text] [Related]
9. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Sosman JA; Sondak VK
Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
[TBL] [Abstract][Full Text] [Related]
10. Genetically modified tumour vaccines (GMTV) in melanoma clinical trials.
Nawrocki S; Murawa P; Malicki J; Kapcinska M; Gryska K; Izycki D; Kaczmarek A; Laciak M; Czapczyk A; Karczewska A; Rose-John S; Mackiewicz A
Immunol Lett; 2000 Sep; 74(1):81-6. PubMed ID: 10996632
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
13. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
[TBL] [Abstract][Full Text] [Related]
14. Review: dendritic cell immunotherapy for melanoma.
Hadzantonis M; O'Neill H
Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
[TBL] [Abstract][Full Text] [Related]
15. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
Sondak VK; Sabel MS; Mulé JJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
[TBL] [Abstract][Full Text] [Related]
17. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.
Melcher A; Todryk S; Bateman A; Chong H; Lemoine NR; Vile RG
Cancer Res; 1999 Jun; 59(12):2802-5. PubMed ID: 10383135
[TBL] [Abstract][Full Text] [Related]
18. Tumor vaccines: a role in preventing recurrence in melanoma?
Sabel MS; Sondak VK
Am J Clin Dermatol; 2002; 3(9):609-16. PubMed ID: 12444803
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic vaccines against melanoma and colorectal cancer.
Tartaglia J; Bonnet MC; Berinstein N; Barber B; Klein M; Moingeon P
Vaccine; 2001 Mar; 19(17-19):2571-5. PubMed ID: 11257394
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
Carreno BM; Magrini V; Becker-Hapak M; Kaabinejadian S; Hundal J; Petti AA; Ly A; Lie WR; Hildebrand WH; Mardis ER; Linette GP
Science; 2015 May; 348(6236):803-8. PubMed ID: 25837513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
